NVO Company Profile and Key Details

NYSE : NVO

Novo Nordisk A/S

$44.28

At Close 4:00 PM

58.48

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Novo Nordisk A/S (NVO) stock remained unchanged at $44.28 a share on NYSE. The stock opened at $44.38, fluctuating between $44.08 to $44.84 during the session.

Stock Snapshot

44.28

Prev. Close

196.77B

Market Cap

44.08

Day Low

10.35

P/E Ratio

4.28

EPS (TTM)

15.68

Cash Flow per Share

44.38

Open

4.44B

Number of Shares

44.84

Day High

100%

Free Float in %

23.87

Book Value

9.35M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 19, 2026	44.36	44.84	44.08	44.28	9.63M
May 18, 2026	44.63	45.09	43.97	44.28	15.34M
May 15, 2026	45.40	45.50	44.25	44.74	16.36M
May 14, 2026	46.79	46.84	45.54	45.80	13.26M
May 13, 2026	47.07	47.21	46.65	47.08	9.99M
May 12, 2026	46.99	47.11	46.29	47.00	14.19M
May 11, 2026	46.69	47.79	46.27	46.40	17.74M
May 08, 2026	45.97	46.14	45.19	46.07	11.85M
May 07, 2026	46.55	47.08	45.75	45.80	16.46M
May 06, 2026	46.31	47.55	45.53	45.76	29.99M
May 05, 2026	44.53	45.12	44.21	44.87	21.09M
May 04, 2026	44.15	44.58	43.84	44.39	18.55M
Apr 30, 2026	41.85	42.86	41.65	42.22	25.03M
Apr 29, 2026	40.76	40.78	39.70	40.29	15.89M
Apr 28, 2026	41.30	42.08	41.10	41.17	16.34M
Apr 27, 2026	40.76	41.67	40.55	41.20	19.29M
Apr 23, 2026	39.13	39.20	38.02	38.52	12.21M
Apr 22, 2026	39.15	39.33	38.85	39.15	17.43M
Apr 21, 2026	40.14	40.20	38.70	39.42	25.05M
Apr 20, 2026	40.51	40.85	40.26	40.46	10.17M

Contact Details

Bagsvaerd, 2880

Denmark

https://www.novonordisk.com 454 444 8888

About Company

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Peers

LLY

33.5+3.39%

Eli Lilly and Company$1,021.59 JNJ

1.08+0.47%

Johnson & Johnson$230.00 ABBV

4.45+2.13%

AbbVie Inc.$213.86 AZN

0.72+0.39%

AstraZeneca PLC$184.64 NVS

1.29+0.86%

Novartis AG$150.44 MRK

1.71+1.52%

Merck & Co., Inc.$114.27 BMY

1+1.74%

Bristol-Myers Squibb Company$58.31 GSK

0.79+1.57%

GSK plc$51.05 PFE

0.35+1.38%

Pfizer Inc.$25.68 OGN

-4.19617e-70.00%

Organon & Co.$13.42

Company Overview

The stock is currently mid-range between its 52-week high and low $35.12 and $81.44. With a market capitalization of about $196.77 billion, Novo Nordisk A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 20.56 million shares, volume is running light vs its 52-week average. Headquartered in Bagsvaerd, None, Novo Nordisk A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Maziar Mike Doustdar, the company employs approximately 77,406 people and listed since April 30, 1981. Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -21.65%, SMA50 -28.41%, SMA200 -34.36%). The stock’s 14-day RSI is 24.12 (weak momentum), while the ATR of 2.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.06% below its high and over -0.08% above its low. Average 10-day trading volume of 13.79 million shares is below the 3-month average of 19.87 million, indicating normal recent market interest.

Valuation Metrics

Novo Nordisk A/S trades at a P/E ratio of 10.44, slightly below the S&P 500 average, with a price-to-sales ratio of 3.89 and a price-to-book ratio of 6.27 trading at moderately above to book value. The P/FCF stands at 41.06, also above market averages.

Dividend & Fair Value

Novo Nordisk A/S last paid a dividend of 1.8 per share, this equals a trailing yield of roughly 7.22%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $76.78. This means the shares are trading below this model’s fair value.

Shareholding & Insider Activity

Novo Nordisk A/S has 3.37 billion shares outstanding. The public float is 3.19 billion shares, elevated short interest at 0.62% of float. This equals 21.02 million shares. The short ratio is 0.89 days. Institutional investors hold 9.36% of the float. Insiders own 0.01%.

Financial & Profitability Overview

Over the trailing twelve months, Novo Nordisk A/S generated $232.26B in revenue, or $51.67 per share. Gross margin was 84.60%, operating margin 44.16%, and net profit margin 36.03%. Returns are exceptional, with ROA at 26.61% and ROE at 78.53%.
On valuation metrics, Novo Nordisk A/S trades at a P/E of 10.44, P/S of 3.89 and P/B of 6.27. Liquidity is tight, with a current ratio of 0.79 and quick ratio of 0.56. Operationally, the company’s inventory turnover is 1.16 and cash conversion cycle is -395.71 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.72, supported by a cash flow-to-debt ratio of 0.81.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Novo Nordisk A/S posted revenue of $232.26B, down slightly from $176.95B in the prior quarter. Gross profit was $196.50B (margin 84.60%). Operating income was $102.57B (margin 44.2%). Net income was$83.68B (EPS $18.67).
The company ended the quarter with $30.23B in cash and short-term investments, a total debt of $27.01B, and net debt of $12.61B. Total assets were $314.49B, with equity of $106.56B. Financials further reflected robust performance, with operating cash flow of $108.91B, free cash flow of $70.01B, and capital expenditures of - $38.90B.

Price Forecast & Outlook

Our AI price prediction model suggests that Novo Nordisk A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.07%, with price expected at $48.74 by June 02, 2026, within a range of $47.43 to $50.04 3-Month Outlook: Projected rise of 30.01%, reaching $57.57 by August 17, 2026, with a range of $52.13 to $61.65. 1-Year Outlook: Projected loss of -54.38%, with price at $20.20 by May 19, 2027, within a range of $11.29 to $28.92.

Key Takeaways

Novo Nordisk A/S (NYSE:NVO) shares are up 19.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novo Nordisk A/S trading at a premium to the broader market with a P/E of 10.44. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $111.14, suggesting 150.99% upside. Our AI forecast model points to short-term strength (10.07% over two weeks), a medium-term rise (30.01% over three months), and a longer-term loss (-54.38% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Novo Nordisk A/S (NVO) stock price?

Novo Nordisk A/S (NYSE: NVO) stock price is $44.28 in the last trading session. During the trading session, NVO stock reached the peak price of $44.84 while $44.08 was the lowest point it dropped to. The percentage change in NVO stock occurred in the recent session was 0% while the dollar amount for the price change in NVO stock was $0.00.

NVO's industry and sector of operation?

The NYSE listed NVO is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Novo Nordisk A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NVO?

No Data

How NVO did perform over past 52-week?

NVO's closing price is 26.08% higher than its 52-week low of $35.12 where as its distance from 52-week high of $81.44 is -45.63%.

How many employees does NVO have?

Number of NVO employees currently stands at 77,406.

Link for NVO official website?

Official Website of NVO is: https://www.novonordisk.com

How do I contact NVO?

NVO could be contacted at phone 454 444 8888 and can also be accessed through its website. NVO operates from Novo Alle 1, Bagsvaerd, 2880, Denmark.

How many shares of NVO are traded daily?

NVO stock volume for the day was 9.35M shares. The average number of NVO shares traded daily for last 3 months was 20.56M.

What is the market cap of NVO currently?

The market value of NVO currently stands at $196.77B with its latest stock price at $44.28 and 4.44B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	77406
Beta	0.27
Sales or Revenue	$232.26B
5Y Sales Change%	1.242%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

NVO Company Profile and Key Details

Novo Nordisk A/S

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook